JPH01313412A - Skin cosmetic - Google Patents
Skin cosmeticInfo
- Publication number
- JPH01313412A JPH01313412A JP14419688A JP14419688A JPH01313412A JP H01313412 A JPH01313412 A JP H01313412A JP 14419688 A JP14419688 A JP 14419688A JP 14419688 A JP14419688 A JP 14419688A JP H01313412 A JPH01313412 A JP H01313412A
- Authority
- JP
- Japan
- Prior art keywords
- tocopherol
- skin
- camphor
- glycerin
- cosmetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 31
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 44
- 235000011187 glycerol Nutrition 0.000 claims abstract description 22
- 229960000846 camphor Drugs 0.000 claims abstract description 19
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 15
- 229930008380 camphor Natural products 0.000 claims abstract description 15
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 14
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 14
- 239000011732 tocopherol Substances 0.000 claims abstract description 14
- 229930003799 tocopherol Natural products 0.000 claims abstract description 13
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims abstract description 12
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960001295 tocopherol Drugs 0.000 claims abstract description 8
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000010384 tocopherol Nutrition 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 14
- 230000000694 effects Effects 0.000 abstract description 16
- 229960000984 tocofersolan Drugs 0.000 abstract description 10
- 229940087168 alpha tocopherol Drugs 0.000 abstract description 9
- 230000017531 blood circulation Effects 0.000 abstract description 9
- 239000002076 α-tocopherol Substances 0.000 abstract description 9
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 6
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 abstract description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 abstract description 3
- 229960000458 allantoin Drugs 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 abstract description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 abstract description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 abstract description 2
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 abstract description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 abstract description 2
- 235000020778 linoleic acid Nutrition 0.000 abstract description 2
- 235000004835 α-tocopherol Nutrition 0.000 abstract description 2
- 206010040849 Skin fissures Diseases 0.000 abstract 2
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 abstract 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 28
- 230000003020 moisturizing effect Effects 0.000 description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 235000019149 tocopherols Nutrition 0.000 description 6
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 6
- 229940075507 glyceryl monostearate Drugs 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- -1 Polyoxyethylene Polymers 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000008117 stearic acid Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000001116 FEMA 4028 Substances 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 3
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 3
- 229960004853 betadex Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- KVYGGMBOZFWZBQ-UHFFFAOYSA-N benzyl nicotinate Chemical compound C=1C=CN=CC=1C(=O)OCC1=CC=CC=C1 KVYGGMBOZFWZBQ-UHFFFAOYSA-N 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- WGVKWNUPNGFDFJ-DQCZWYHMSA-N β-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C WGVKWNUPNGFDFJ-DQCZWYHMSA-N 0.000 description 2
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229950004580 benzyl nicotinate Drugs 0.000 description 1
- 229940066595 beta tocopherol Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- SXPWTBGAZSPLHA-UHFFFAOYSA-M cetalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SXPWTBGAZSPLHA-UHFFFAOYSA-M 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 235000010389 delta-tocopherol Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-DYCDLGHISA-N deuterio acetate Chemical compound [2H]OC(C)=O QTBSBXVTEAMEQO-DYCDLGHISA-N 0.000 description 1
- ZLSFWAPBBIIMKI-KVINTPOGSA-M dipotassium;(2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxido-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound [K+].[K+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H]([O-])C1(C)C ZLSFWAPBBIIMKI-KVINTPOGSA-M 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000007680 β-tocopherol Nutrition 0.000 description 1
- 239000011590 β-tocopherol Substances 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
- 239000002446 δ-tocopherol Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Abstract
Description
【発明の詳細な説明】
産業上の利用分野
本発明は優れた肌荒れ防止効果を有する皮膚化粧料に関
する。更に詳しくは、本発明は主成分としてグリセリン
、トコフェロールまたはその誘導体、およびカンフルを
配合した皮膚化粧料に関する。DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to a skin cosmetic having an excellent effect of preventing rough skin. More specifically, the present invention relates to a skin cosmetic containing glycerin, tocopherol or a derivative thereof, and camphor as main ingredients.
従来の技術および課題
元来、肌荒れを防止するには、保湿効果のある薬剤を肌
に塗布して表皮の保湿力を高めて防止する方法と、皮膚
の毛細血管に対して血行促進作用のある薬剤を塗布して
末梢血管の血行を良くすることにより肌荒れを改善する
方法が知られている。Conventional technology and issues There are two ways to prevent skin roughness: applying a moisturizing agent to the skin to increase the moisturizing ability of the epidermis, and a method that increases blood circulation to the skin's capillaries. A method of improving rough skin by applying a drug to improve blood circulation in peripheral blood vessels is known.
しかしながら、これらの方法には各々、長所、短所があ
り、保湿効果による方法では、即効性はあるもののその
肌荒れ防止効果の持続性は少なく、一方、血行促進作用
による方法では、−度肌荒れが改善されると、その持続
性はあるものの即効性は少ない。However, each of these methods has its advantages and disadvantages; methods that rely on moisturizing effects have an immediate effect, but their effect on preventing rough skin is short-lived, while methods that promote blood circulation improve skin roughness by - When this happens, the effect is long-lasting but not immediate.
グリセリンが皮膚に対して高い保湿性を有することは従
来よりよく知られている。しかしながら、かかる保湿性
は短期的なものであり、毛細血管の血行促進により持続
性のある肌荒れ改善を行うものではなく、保湿による肌
荒れ改善は持続性に欠け、グリセリン単独では未だ充分
な肌荒れ改善効果は得られない。It has been well known that glycerin has high moisturizing properties for the skin. However, such moisturizing properties are short-term, and do not provide long-lasting improvement in rough skin by promoting blood circulation in capillaries. Improvement in rough skin due to moisturization lacks sustainability, and glycerin alone is still insufficient to improve rough skin. cannot be obtained.
他方、トコフェロール類およびカンフルは、その血行促
進作用が既知であり、種々の化粧料に配合されているが
、その作用は緩和であり、肌目体の血行を促進し皮膚本
来の機能を高めて肌荒れ改善を図るものであり、即効的
な効果はこれらの薬剤たけては不十分である。On the other hand, tocopherols and camphor are known to have a blood circulation-promoting effect and are included in various cosmetics, but their effects are mild, promoting blood circulation in the skin, eyes, and body, and enhancing the skin's original functions. These drugs aim to improve rough skin, and the immediate effects of these drugs are insufficient.
本発明者らは前記問題点につき検討を重ねた結果、グリ
セリン、トコフェロール類およびカンフルを組合わせる
ことにより、極めて即効的かつ持続性のある肌荒れ改善
効果が得られることを知り、本発明を完成するに至った
。As a result of repeated studies on the above-mentioned problems, the present inventors found that by combining glycerin, tocopherols, and camphor, an extremely immediate and long-lasting effect on improving rough skin could be obtained, and the present invention was completed. reached.
課題を解決するための手段
本発明は、グリセリン15〜40重量%、トコフェロー
ルまたはその誘導体、およびカンフルを含有することを
特徴とする皮膚化粧料を提供するものである。Means for Solving the Problems The present invention provides a skin cosmetic containing 15 to 40% by weight of glycerin, tocopherol or a derivative thereof, and camphor.
本発明化粧料にはグリセリン15〜40重量%が配合さ
れる。グリセリン配合量が15重量%未満では十分な即
効性のある保湿効果が得られず、また40重量%を超え
ると、使用感に問題(べたつき感)があり、乳化系の安
定性もよくない。The cosmetic composition of the present invention contains 15 to 40% by weight of glycerin. If the glycerin content is less than 15% by weight, a sufficient immediate moisturizing effect cannot be obtained, and if it exceeds 40% by weight, there will be problems with the feeling of use (stickiness) and the stability of the emulsion system will be poor.
一方、本発明皮膚化粧料に配合されるトコフェロールと
しては、α−トコフェロール、β−トコフェロール、γ
−トコフェロール、δ−トコフェロールなどが挙げられ
る。これらは天然物由来のものであっても、また合成に
よって得られたものでもよく、単独または2種以上が混
合して用いられる。On the other hand, the tocopherols to be incorporated into the skin cosmetics of the present invention include α-tocopherol, β-tocopherol, γ-tocopherol,
-tocopherol, δ-tocopherol, and the like. These may be derived from natural products or may be obtained by synthesis, and may be used alone or in combination of two or more.
また、トコフェロール誘導体としては、酢酸dQ−α−
トコフェロール、リノール酸d12−α−トコフェロー
ル、リルイン酸dQ−α−トコフェロール、ニコヂン酸
dρ−α−トコフェロール、アスコルビン酸dQ−α−
トコフェロール、コハク酸d12−α−トコフェロール
などが挙げられる。In addition, as tocopherol derivatives, acetic acid dQ-α-
Tocopherol, d12-α-tocopherol linoleate, dQ-α-tocopherol liruinate, dρ-α-tocopherol nicodinate, dQ-α-ascorbic acid
Examples include tocopherol, d12-α-tocopherol succinate, and the like.
かかるトコフェロール類の配合量は、化粧料中0.1〜
0.7重量%であるのが好ましい。配合量が0.1重量
%未満では血行促進作用が不十分で肌荒れ防止効果がな
く、一方、0.7重量%を超えても効果は増大しない。The content of such tocopherols in cosmetics ranges from 0.1 to
Preferably it is 0.7% by weight. If the amount is less than 0.1% by weight, the blood circulation promoting effect is insufficient and there is no effect on preventing rough skin, while if it exceeds 0.7% by weight, the effect will not increase.
また、本発明化粧料に配合されるカンフル類としては、
d−カンフル、dQ−カンフルが挙げられる。In addition, camphor compounds to be added to the cosmetics of the present invention include:
Examples include d-camphor and dQ-camphor.
かかるカンフル類の配合量は化粧料中OI〜07重量%
であるのが好ましい。配合量が01重量%未満では血行
の促進による肌荒れ防止効果がなく、一方、07重量%
を超えると皮膚に対する刺激感が生じ好ましくない。The amount of camphor compounded in cosmetics is OI ~ 07% by weight.
It is preferable that If the blending amount is less than 0.01% by weight, there is no effect of preventing rough skin by promoting blood circulation, while on the other hand, if the amount is less than 0.07% by weight,
Exceeding this level is undesirable as it may cause irritation to the skin.
本発明化粧料には、グリセリンが15〜40重量%と多
量に配合され、クリーム、乳液等の乳化化粧料では系の
分離を引き起こしやすくなる。また、トコフェロール類
、カンフル等の成分は化粧水、美容液等の可溶化化粧料
では系に入りにくくなる。そのため、乳化剤、可溶化剤
を多く配合する必要があるが、乳化剤、可溶化剤が多く
なると製品の皮膚刺激が高くなる。The cosmetic composition of the present invention contains a large amount of glycerin (15 to 40% by weight), which tends to cause system separation in emulsified cosmetic compositions such as creams and milky lotions. In addition, components such as tocopherols and camphor are difficult to enter the system in solubilized cosmetics such as lotions and serums. Therefore, it is necessary to incorporate a large amount of emulsifiers and solubilizers, but when the amount of emulsifiers and solubilizers increases, the product becomes more irritating to the skin.
そのため、本発明化粧料にはさらにシクロデキストリン
類を配合することで、グリセリンやトコフェロール類、
カンフルを配合することにより生じる系の不安定性を防
止する。該シクロデキストリンとしては、α−シクロデ
キストリン、β−シクロデギストリン、γ−ンクロデキ
ストリンまたは、これらの混合物などが挙げられ、これ
らの1種または2種以上が配合されてよい。かかるシク
ロデキストリンの配合量は01〜5重量%であるのが好
ましい。配合量が0.1重量%未満ては安定性改善の効
果が発現せず、一方、5重量%を超えると、水相に溶解
せず、結晶となって析出し、使用面で問題を生じる。Therefore, by further adding cyclodextrins to the cosmetics of the present invention, glycerin, tocopherols,
Prevents system instability caused by incorporating camphor. Examples of the cyclodextrin include α-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, and mixtures thereof, and one or more of these may be blended. The amount of such cyclodextrin blended is preferably 0.1 to 5% by weight. If the blending amount is less than 0.1% by weight, the effect of improving stability will not be exhibited, while if it exceeds 5% by weight, it will not dissolve in the aqueous phase and will precipitate as crystals, causing problems in use. .
さらに、本発明化粧料には、処方に応じて消炎作用を有
する種々の成分を配合しても良い。かかる消炎成分とし
ては、例えば、アラントイン、アロエ末、イクタモール
グアイアズレン及びその誘導体、グリチルリチン酸及び
その誘導体、グリチルレヂン酸及びその誘導体、ザリチ
ル酸メチル、ステアリン酸グリチルレヂニルヒノキヂオ
ールなどが挙げられる。Furthermore, the cosmetic composition of the present invention may contain various ingredients having anti-inflammatory effects depending on the formulation. Examples of such anti-inflammatory ingredients include allantoin, aloe powder, ictamolguaiazulene and its derivatives, glycyrrhizinic acid and its derivatives, glycyrrhizic acid and its derivatives, methyl salicylate, glycyrrhedinylhinokidiol stearate, and the like.
また、本発明化粧料には、他の種々の血行促進作用を有
する成分を併用しても良い。かかる成分としては、例え
ば、γ−オリザノール、ニコチン酸、ニコチン酸アミド
、ニコチン酸ベンジル、ρ−メントール、dQ−メント
ールなどが挙げられる。Furthermore, the cosmetic composition of the present invention may contain various other components having blood circulation promoting effects. Examples of such components include γ-oryzanol, nicotinic acid, nicotinamide, benzyl nicotinate, ρ-menthol, dQ-menthol, and the like.
つぎに、本発明化粧料の保湿性、使用感について試験し
た結果を示す。後記第1表に示す成分を配合して試験組
成物を調製し、下記の方法で評価した。第1表中の配合
量は重量%を意味する。Next, the results of testing the moisturizing properties and feel of the cosmetics of the present invention will be shown. A test composition was prepared by blending the components shown in Table 1 below, and evaluated by the following method. The blending amounts in Table 1 mean % by weight.
試料の調製法:
成 分 重量%
油相: ミツロウ 2.5ス
テアリン酸 3.0スクワラン
8.0バルミチン酸イソプロピル
3.0オクタン酸セチル 6.0
セタノール 3.0水相: パ
ラオキシ安息香酸エチル 0.3トリエタノール
アミン 0.6グリセリン
第1表に記載精製水 残部
その他の成分
トコフェロール誘導体 第1表に記載d−カ
ンフルまたはdQ−カンフル 〃β−シクロデキス
トリン 〃グリチルレチン酸ステアリル
〃アラントイン 〃σ
−メントール 〃上記油相と
水相を共に75℃に加熱し、両相を混合して均一に分散
した後冷却し、45℃でその他の成分を加え、さらに冷
却し試料を得る。Sample preparation method: Ingredients Weight % Oil phase: Beeswax 2.5 Stearic acid 3.0 Squalane
8.0 Isopropyl Valmitate
3.0 Cetyl octoate 6.0
Setanol 3.0 Aqueous phase: Ethyl paraoxybenzoate 0.3 Triethanolamine 0.6 Glycerin
Purified water listed in Table 1 Remainder Other components Tocopherol derivatives d-camphor or dQ-camphor listed in Table 1 β-cyclodextrin Stearyl glycyrrhetinate
〃Allantoin〃σ
-Menthol〃The above oil phase and water phase are both heated to 75°C, both phases are mixed and dispersed uniformly, and then cooled. Other components are added at 45°C, and further cooled to obtain a sample.
10名の皮膚健常人の上腕部に各試料0.39を塗布し
た。保湿性の測定は5kin SurfaceHydr
ometer I B−355(I B S社製)を用
い、塗布直後および塗布の翌日(24時間後)に各コン
ダクタンス値(単位二μd)を測定することにより行っ
た。測定は気温20℃、湿度60%の部屋にて行った。0.39 of each sample was applied to the upper arms of 10 people with healthy skin. Moisture measurement is done using 5kin Surface Hydr.
Each conductance value (unit: 2 μd) was measured immediately after coating and the next day (24 hours after coating) using ometer I B-355 (manufactured by IBS). The measurements were performed in a room with a temperature of 20°C and a humidity of 60%.
結果を第1表に示す。The results are shown in Table 1.
18名の女性パネラ−に対し第1表の各試料を塗布した
後の皮膚の状態を「肌荒れ改善効果」、「使用感」、「
総合的評価」の3項目につきそれぞれよいと感じるか否
か評価した。各項目につきよいと感じた人の人数を第1
表に示した。After applying each sample in Table 1 to 18 female panelists, the skin condition was evaluated as "improving effect on rough skin,""feeling of use," and "
We evaluated whether each of the three items in the "Overall Evaluation" felt good or not. The first is the number of people who felt that each item was answered correctly.
Shown in the table.
第1表のコンダクタンス値かられかるように、グリセリ
ン、トコフェロールおよびカンフルを配合した試験例1
〜Bは、塗布翌日においても高い保湿能を示す。一方、
グリセリンを含むものの前記必須成分のいずれかを欠く
比較試験例1.2および4、あるいはグリセリン配合量
が低い比較試験例3では、塗布直後の保湿能には優れる
ものの24時間後の保湿効果は低い。また、直後および
24時間後の両方のコンダクタンス値が高いものは、[
肌荒れ改善効果がある4と感じた人数も多く、肌荒れ改
善が認められる。Test Example 1 containing glycerin, tocopherol and camphor as seen from the conductance values in Table 1
~B shows high moisturizing ability even on the day after application. on the other hand,
Comparative Test Examples 1, 2 and 4, which contain glycerin but lack any of the above essential components, or Comparative Test Example 3, which contains a low amount of glycerin, have excellent moisturizing ability immediately after application, but have a low moisturizing effect after 24 hours. . In addition, those with high conductance values both immediately and after 24 hours are [
Many people felt that it had a 4 rating, indicating that it had an effect on improving rough skin.
本発明の皮膚化粧料は公知の方法によりクリーム、乳液
、化粧液、化粧水、パック、頭皮用育毛料などの形態に
製造される。The skin cosmetics of the present invention are manufactured in the form of creams, milky lotions, lotions, lotions, packs, scalp hair growth products, etc. by known methods.
なお、本発明の化粧料には、さらにその種類に応じ、本
発明化粧料の性能を損なわない範囲において適宜公知の
成分が配合されてよい。In addition, the cosmetic composition of the present invention may further contain known ingredients as appropriate, depending on the type thereof, within a range that does not impair the performance of the cosmetic composition of the present invention.
大旗外
つぎに本発明を実施例にもとづきさらに具体的に説明す
る。Next, the present invention will be explained in more detail based on examples.
下記の組成により、常法にもとづき皮膚化粧料を調製し
た。A skin cosmetic was prepared according to a conventional method using the following composition.
実施例1(クリーム)
成 分 ■%酢酸d
Q−α−トコフェロール 0.20d−
カンフル 020流動
パラフイン 18.00パラフ
イン 500ステアリン
酸 3.00セタノール
300カルボキシ
ビニルポリマー 0.30水酸化カリウ
ム 020モノステアリン酸
ポリ特ジエチレンソルビタン (20E、O,)
1 .5 0モノステアリン酸グリセリ
ン 3.00β−シクロデキストリン
0.70グリセリン
25.00パラオキシ安息香酸エチル
0.30香 料
02010一
実施例2(乳液)
成 分 重量%リノー
ル酸dQ−α−トコフェロール 0.30dQ
−カンフル 0.30
ステアリン酸 100セ
タノール 1.00
オリーブ油 3.00
スクワラン 6.00白
色ワセリン 2.00自
己乳化型モノステアリン酸グリセリン 1.50モノ
ステアリン酸ポリオAジエチレン゛ノルピタン (20
E、O,) 1 .0 0シクロデ
キストリン混合物 1.00グリセリン
18.00パラオキシ安息
香酸エヂル 0.20香 料
0.IO実施例3(ヘア
クリーム)
一収一一外一 重量%ニコチ
ン酸d(1−α−トコフェロ−fiv 0
.20=11−
dQ−カンフル 0
.25白色ワセリン
8.00ミリスチン酸イソプロピル
8.00セタノール
300流動パラフイン
is、o。Example 1 (cream) Ingredients ■% Acetic acid d
Q-α-tocopherol 0.20d-
Camphor 020 Liquid Paraffin 18.00 Paraffin 500 Stearic Acid 3.00 Cetol 300 Carboxy Vinyl Polymer 0.30 Potassium Hydroxide 020 Polyspecial Diethylene Sorbitan Monostearate (20E, O,)
1. 50 Glyceryl monostearate 3.00 β-cyclodextrin
0.70 glycerin
25.00 Ethyl paraoxybenzoate
0.30 fragrance
02010-Example 2 (emulsion) Ingredients Weight % linoleic acid dQ-α-tocopherol 0.30 dQ
- Camphor 0.30
Stearic acid 100 Setanol 1.00
Olive oil 3.00
Squalane 6.00 White petrolatum 2.00 Self-emulsifying glyceryl monostearate 1.50 PolyA diethylene norpitane monostearate (20
E, O,) 1. 0 0 Cyclodextrin mixture 1.00 Glycerin 18.00 Ezyl paraoxybenzoate 0.20 Flavor
0. IO Example 3 (Hair Cream) Yield 1 External 1 Weight % Nicotinic acid d (1-α-tocophero-fiv 0
.. 20=11-dQ-camphor 0
.. 25 white petrolatum
8.00 Isopropyl myristate
8.00 Cetanol
300 liquid paraffin
is, o.
ポリオキシエチレン(20E、O,)セチルエーテル
2.00ポリれジエチレン(15E、o、)グリセリル
モノステアレー) 2.5
0グリセリン 200β
−シクロデキストリン 0.6香
料 0.3
0安息香酸ナトリウム 0.4
5100.00
実施例4(化粧液)
成 分 重量%dQ
−α−トコフェロール 0.20
dQ−カンフル 0
.20ポリオキシエチレン(20E、O,)硬化ヒマシ
油 l、00グリセリン
18.00シクロデキストリン混合物
1.00エタノール
12.00香 料
0.15実施例5(クリーム)
成 分 重量%d−
カンフル 0・30
酢酸dQ−α−トコフェロール 0.
20グリチルレチン酸ステアリル 0.
10スクワラン 10.
00オリーブ油
8.00ステアリン酸
4.OOセタノール
2.00親油型モノステアリン酸グリセリン
3.00ポリれジエチレン(20E、O,)グリセ
リルモノステアレート 2.
00β−シクロデキストリン 0
.50濃グリセリン 25
.00パラオキシ安息香酸エチル 0
.3014一
実施例6(化粧液)
成 分 重量%d−
カンフル 0.35
酢酸d12−α−トコフェロール 0.
20グリチルレチン酸ジカリウム 0.
40グリセリン t s、
o 。Polyoxyethylene (20E, O,) cetyl ether
2.00 polyethylene (15E, o, glyceryl monostearate) 2.5
0 glycerin 200β
-Cyclodextrin 0.6 Flavor 0.3
0 Sodium benzoate 0.4
5100.00 Example 4 (cosmetics) Ingredients Weight% dQ
-α-tocopherol 0.20
dQ-camphor 0
.. 20 polyoxyethylene (20E, O,) hydrogenated castor oil l, 00 glycerin
18.00 Cyclodextrin mixture
1.00 ethanol
12.00 fragrance
0.15 Example 5 (cream) Ingredients Weight% d-
Camphor 0.30
dQ-α-tocopherol acetate 0.
20 Stearyl glycyrrhetinate 0.
10 Squalane 10.
00olive oil
8.00 stearic acid
4. OO cetanol
2.00 Lipophilic glyceryl monostearate
3.00 polydiethylene (20E, O,) glyceryl monostearate 2.
00β-cyclodextrin 0
.. 50 concentrated glycerin 25
.. 00 Ethyl paraoxybenzoate 0
.. 3014-Example 6 (cosmetic liquid) Ingredients Weight% d-
Camphor 0.35
d12-α-tocopherol acetate 0.
20 Dipotassium glycyrrhetinate 0.
40 glycerin ts,
o.
ポリオキシエチレン硬化ヒマシ油(40E、O,)
0 、80エタノール
10.00パラオキシ安息香酸エチル
0.05香 料
0.10発明の効果
本発明の皮膚化粧料は保湿効果に優れ、肌荒れ防止に顕
著な効果を奏する。Polyoxyethylene hydrogenated castor oil (40E, O,)
0,80 ethanol
10.00 Ethyl paraoxybenzoate
0.05 fragrance
0.10 Effects of the Invention The skin cosmetics of the present invention have excellent moisturizing effects and are significantly effective in preventing rough skin.
特許出願人 サンスター株式会社Patent applicant: Sunstar Co., Ltd.
Claims (2)
たはその誘導体、およびカンフルを含有することを特徴
とする皮膚化粧料。(1) A skin cosmetic containing 15 to 40% by weight of glycerin, tocopherol or a derivative thereof, and camphor.
する前記第(1)項の皮膚化粧料。(2) The skin cosmetic composition according to item (1) above, containing 0.1 to 5.0% by weight of cyclodextrin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14419688A JP2556730B2 (en) | 1988-06-10 | 1988-06-10 | Skin cosmetics |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14419688A JP2556730B2 (en) | 1988-06-10 | 1988-06-10 | Skin cosmetics |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01313412A true JPH01313412A (en) | 1989-12-18 |
JP2556730B2 JP2556730B2 (en) | 1996-11-20 |
Family
ID=15356448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP14419688A Expired - Fee Related JP2556730B2 (en) | 1988-06-10 | 1988-06-10 | Skin cosmetics |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2556730B2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06234628A (en) * | 1993-02-09 | 1994-08-23 | Kao Corp | External agent for skin |
JP2003238402A (en) * | 2002-01-10 | 2003-08-27 | Wacker Chemie Gmbh | COMPLEX OF beta- OR gamma-CYCLODEXTRIN AND alpha-TOCOPHEROL AND METHOD FOR PRODUCING THE SAME AND COSMETIC CONTAINING THE SAME |
JP2008081505A (en) * | 2007-11-02 | 2008-04-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
JP2009209102A (en) * | 2008-03-05 | 2009-09-17 | Shiseido Co Ltd | O/w emulsion cosmetic |
JP2010143884A (en) * | 2008-12-22 | 2010-07-01 | Shiseido Co Ltd | Chapped skin improving agent |
-
1988
- 1988-06-10 JP JP14419688A patent/JP2556730B2/en not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06234628A (en) * | 1993-02-09 | 1994-08-23 | Kao Corp | External agent for skin |
JP2003238402A (en) * | 2002-01-10 | 2003-08-27 | Wacker Chemie Gmbh | COMPLEX OF beta- OR gamma-CYCLODEXTRIN AND alpha-TOCOPHEROL AND METHOD FOR PRODUCING THE SAME AND COSMETIC CONTAINING THE SAME |
JP2008081505A (en) * | 2007-11-02 | 2008-04-10 | Rohto Pharmaceut Co Ltd | External preparation for skin |
JP2009209102A (en) * | 2008-03-05 | 2009-09-17 | Shiseido Co Ltd | O/w emulsion cosmetic |
JP2010143884A (en) * | 2008-12-22 | 2010-07-01 | Shiseido Co Ltd | Chapped skin improving agent |
Also Published As
Publication number | Publication date |
---|---|
JP2556730B2 (en) | 1996-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5153230A (en) | Topical skin cream composition | |
TWI287995B (en) | Dermatological composition containing co-enzyme Q as active ingredient | |
JP2001518070A (en) | Cosmetic or pharmaceutical preparation with reduced sticky feel | |
JPH10503780A (en) | Anti acne cosmetic composition | |
JPS62292710A (en) | Skin cosmetic | |
KR101590803B1 (en) | Cosmetic composition for quick whitening or improving skin tone comprising calamine | |
JP2002501010A (en) | Cosmetic or pharmaceutical preparation with reduced stickiness, comprising a glycerol ester of an α-hydroxycarboxylic acid and a saturated fatty acid | |
JPH01313412A (en) | Skin cosmetic | |
JP2008063295A (en) | Skin care preparation containing platinum/silver colloid | |
JPH07101844A (en) | Multilayered emulsion | |
JPH01283208A (en) | Beautifying cosmetic | |
JP2004307434A (en) | Water-resistant o/w emulsion composition and water-resistant o/w cosmetic having ultraviolet prevention effect and containing water-resistant o/w emulsion composition therein | |
JP2000256173A (en) | Emulsified cosmetic | |
JP2963285B2 (en) | Gel cosmetics | |
JPS62164609A (en) | Skin cosmetic | |
JPS62226910A (en) | Skin cosmetic | |
JPH03291207A (en) | Dermatic agent for external use | |
JPH10279427A (en) | Moisture-retaining cosmetic material composition | |
JP2781626B2 (en) | Solubilized transparent cosmetic | |
CA2428902A1 (en) | Compositions having comfrey and methods for reducing retinoid-induced skin irritation | |
JP2019131507A (en) | Skin external preparations or cosmetics | |
WO2024071406A1 (en) | Water-in-oil emulsion composition | |
JP2799600B2 (en) | Oily cosmetic for skin | |
CN111132650A (en) | Cosmetic or dermatological water-in-oil emulsions | |
JP3378127B2 (en) | Whitening cosmetics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |